MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)

The McQuade Center for Strategic Research and Development Enters Agreement with Sentinel Oncology to Develop Breakthrough Treatment for Fragile X Syndrome

Retrieved on: 
Thursday, September 2, 2021
Pharmaceutical, Health, Oncology, Other Health, Sentinel, Patient, FXS, Cardiology, LLC, Twitter, Mental health, OAPI, Heart, Organization, 2009 Davis Cup, Creativity, Maintenance, Genetic disorder, Commercialization, Tuberculosis, Neuro-Oncology (journal), Fragile X syndrome, Doctor of Philosophy, Survival, Nephrology, LinkedIn, CNS, Intellectual disability, Lists of diseases, CEO, Development, Therapy, Cancer, Health, Pharmaceutical industry, Fragile X Syndrome, Sentinel Oncology, McQuade Center for Strategic Research and Development (MSRD), FRAGILE X SYNDROME, SENTINEL ONCOLOGY, MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company.

Key Points: 
  • The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company.
  • The McQuade Center for Strategic Research and Development at Otsuka in the U.S. will support the clinical development of a first-in-class therapeutic with the potential to treat Fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics1.
  • We are hopeful that our collaboration can lead to the development of a potential therapeutic for people living with this condition.
  • We are delighted to be collaborating with the MSRD team to advance SOL784 into clinical development said Robert G Boyle, founder and CEO of Sentinel Oncology.

McQuade Center for Strategic Research and Development Enters Collaboration with Aché to Develop Potential Treatment for General Anxiety Disorder and Post-Traumatic Stress Disorder

Retrieved on: 
Tuesday, August 24, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Nephrology, Commercialization, LLC, CNS, Twitter, Innovation Unit, Maintenance, Cardiology, Tuberculosis, Research, Drug discovery, Cosmetics, National university, Doctor of Philosophy, Health, OAPI, Post-traumatic stress disorder, Heart, Mental health, Development, GAD, Creativity, LinkedIn, Patient, Plasma protein binding, PTSD, Pharmaceutical industry, Aché Laboratorios Farmaceuticos S.A., McQuade Center for Strategic Research and Development (MSRD), ACHé LABORATORIOS FARMACEUTICOS S.A., MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)

Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.

Key Points: 
  • Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.
  • We are absolutely thrilled with this collaboration with MSRD, a member of Otsuka, said Vnia Alcantara Machado, president, Ach.
  • We believe MSRDs expertise in early-stage programs and Otsukas global leadership position in CNS will be crucial in the development of Achs ACH000029 for GAD and PTSD.
  • Ach has a dedicated Innovation Unit focused on the research and development of new medicines, generics, and similar drugs.

The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders

Retrieved on: 
Friday, October 30, 2020
Mental health, Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Psychiatry, Psychiatric diagnosis, Psychology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Treatment-resistant depression, Rugen Therapeutics, McQuade Center for Strategic Research and Development (MSRD), Otsuka

The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).

Key Points: 
  • The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).
  • Rugens proprietary technology stems from its novel research into the circuit mechanisms of psychiatric disorders, facilitated by genetic-based animal models.
  • This research has translated into its innovative drug candidate, which has potentially broad application across multiple psychiatric indications.
  • Rugen Holdings (Cayman) Limited, dba Rugen Therapeutics is a biotech company discovering and developing novel, first-in-class, small-molecule drugs with the potential to address multiple psychiatric indications.